[New antithrombotic drugs in cardiovascular disease].
During the past decades, a great bulk of studies have been undertaken to investigate the pathophysiologic mechanisms responsible for thrombus formation. As a consequence, different therapeutic strategies interfering at different levels of the coagulation process have been developed. Many of these compounds did not achieve full development, but others are presently available for the clinician. The present review paper will focus on these new therapeutic strategies developed in the last 10 years.
Cattedra di Cardiologia, Dipartimento di Scienze Cardio-Toraciche e Respiratorie, Seconda Università degli Studi, Napoli. paolo.golino@unina2.it
Paolo
P
Golino
Giovanni
G
Cimmino
Irma
I
Porchetta
Maria
M
Spadera
Marianna
M
Volpe
Raffaele
R
Calabrò
D001384:Azetidines / Q000008:administration & dosage; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D003328:Coronary Thrombosis / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006023:Glycoproteins / Q000008:administration & dosage; D006801:Humans; D010455:Peptides / Q000008:administration & dosage; D011134:Polysaccharides / Q000008:administration & dosage; D011994:Recombinant Proteins / Q000008:administration & dosage
D001384:Azetidines; D005343:Fibrinolytic Agents; D006023:Glycoproteins; D010455:Peptides; D011134:Polysaccharides; D011994:Recombinant Proteins